Follow Our Journey On Social Media
Results Published In Leading Scientific Journals
Nature Reviews Cancer
Approaches from the physical sciences can contribute to the rate at which powerful new diagnostic tools and therapies can be discovered.
Targeting autocrine CCL5–CCR5 axis reprograms immunosuppressive myeloid cells and reinvigorates antitumor immunity
Clinical Cancer Research
Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery
Porous silicon microparticle potentiates anti-tumor immunity by enhancing cross-presentation and inducing type I interferon response
Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Breast Cancer Breakthrough
BrYet CEO Dr. Mauro Ferrari finds that an injectable nanoparticle generator enhances delivery of cancer therapeutics.
BrYet Partners With NerPharMa
BrYet US, Inc. starts a Manufacturing Development Agreement with NerPharMa for its lead product candidate ML-016 against lung and liver metastases from different type of breast cancer.
Panel: Nixon National Cancer Conference
BrYet CEO Dr. Mauro Ferrari discusses changing the future of cancer.
Pioneering Medical Advances with Silicon
BrYet is using silicon as the basis for innovative therapeutics at effective local concentrations with the fewest possible side effects.